New study tracks Finerenone's impact on kidney risk in diabetic patients
NCT ID NCT07554469
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study will follow 500 adults with chronic kidney disease and type 2 diabetes who are taking finerenone, a drug that helps protect the kidneys and heart. Researchers want to see if a tool called the Klinrisk score, which estimates the risk of kidney disease getting worse, improves after 2 years of treatment. The study will collect data from routine doctor visits and monitor any side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Many locations
RECRUITINGMultiple Locations, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- Could a common diabetes drug weaken your bones?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Can a spice and a mindset shift ease diabetic nerve pain?